X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs NOVARTIS - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE NOVARTIS CADILA HEALTHCARE/
NOVARTIS
 
P/E (TTM) x 35.2 347.8 10.1% View Chart
P/BV x 9.1 17.1 52.9% View Chart
Dividend Yield % 0.7 1.7 40.1%  

Financials

 CADILA HEALTHCARE   NOVARTIS
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-16
NOVARTIS
Mar-16
CADILA HEALTHCARE/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs454982 46.3%   
Low Rs305556 54.7%   
Sales per share (Unadj.) Rs96.1252.9 38.0%  
Earnings per share (Unadj.) Rs14.962.1 23.9%  
Cash flow per share (Unadj.) Rs17.863.3 28.2%  
Dividends per share (Unadj.) Rs3.2010.00 32.0%  
Dividend yield (eoy) %0.81.3 64.9%  
Book value per share (Unadj.) Rs52.3363.6 14.4%  
Shares outstanding (eoy) m1,023.7431.96 3,203.2%   
Bonus/Rights/Conversions FV5:1--  
Price / Sales ratio x3.93.0 129.9%   
Avg P/E ratio x25.512.4 206.1%  
P/CF ratio (eoy) x21.312.2 175.2%  
Price / Book Value ratio x7.32.1 343.2%  
Dividend payout %21.516.1 133.7%   
Avg Mkt Cap Rs m388,45824,580 1,580.4%   
No. of employees `00015.40.8 2,053.3%   
Total wages/salary Rs m13,3171,801 739.3%   
Avg. sales/employee Rs Th6,371.110,748.9 59.3%   
Avg. wages/employee Rs Th862.42,395.2 36.0%   
Avg. net profit/employee Rs Th986.12,641.1 37.3%   
INCOME DATA
Net Sales Rs m98,3768,083 1,217.0%  
Other income Rs m941829 113.5%   
Total revenues Rs m99,3178,913 1,114.3%   
Gross profit Rs m23,829234 10,174.6%  
Depreciation Rs m3,02237 8,234.3%   
Interest Rs m4862 27,000.0%   
Profit before tax Rs m21,2621,025 2,074.1%   
Minority Interest Rs m-3000-   
Prior Period Items Rs m517 29.9%   
Extraordinary Inc (Exp) Rs m-251,696 -1.5%   
Tax Rs m5,716752 760.1%   
Profit after tax Rs m15,2261,986 766.6%  
Gross profit margin %24.22.9 836.0%  
Effective tax rate %26.973.4 36.6%   
Net profit margin %15.524.6 63.0%  
BALANCE SHEET DATA
Current assets Rs m44,37612,678 350.0%   
Current liabilities Rs m34,0712,433 1,400.4%   
Net working cap to sales %10.5126.7 8.3%  
Current ratio x1.35.2 25.0%  
Inventory Days Days5433 164.7%  
Debtors Days Days6222 277.3%  
Net fixed assets Rs m47,89669 69,213.9%   
Share capital Rs m1,024160 640.8%   
"Free" reserves Rs m48,74611,460 425.4%   
Net worth Rs m53,51911,621 460.5%   
Long term debt Rs m8,9640-   
Total assets Rs m100,16314,400 695.6%  
Interest coverage x44.7570.5 7.8%   
Debt to equity ratio x0.20-  
Sales to assets ratio x1.00.6 175.0%   
Return on assets %15.713.8 113.6%  
Return on equity %28.417.1 166.5%  
Return on capital %34.323.6 145.5%  
Exports to sales %45.30.7 6,078.8%   
Imports to sales %5.918.6 31.9%   
Exports (fob) Rs m44,53760 73,981.7%   
Imports (cif) Rs m5,8381,503 388.5%   
Fx inflow Rs m44,881186 24,090.7%   
Fx outflow Rs m9,0691,821 498.1%   
Net fx Rs m35,812-1,635 -2,191.0%   
CASH FLOW
From Operations Rs m19,9382,531 787.8%  
From Investments Rs m-9,039-8,270 109.3%  
From Financial Activity Rs m-9,527-386 2,470.1%  
Net Cashflow Rs m1,372-6,125 -22.4%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.3 2.0 415.0%  
FIIs % 5.9 1.6 368.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 21.5 51.2%  
Shareholders   44,069 41,647 105.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   IPCA LABS  SANOFI INDIA  DR. DATSONS LABS  MERCK LTD  GSK PHARMA  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Aug 18, 2017 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS